可切除III期黑色素瘤新辅助帕博利珠单抗治疗后[18F]FDG PET/CT及索引淋巴结反应的预测价值:荷兰最大黑色素瘤中心的真实世界数据
该回顾性分析纳入两个荷兰黑色素瘤中心接受两周期新辅助帕博利珠单抗的可切除III期黑色素瘤患者,评估[18F]FDG PET/CT代谢反应(EORTC标准)及索引淋巴结反应与病理反应(INMC标准)的关系。结果显示CMR患者均达MPR,PMD患者仅12.5%达MPR;索引淋巴结反应与全淋巴结床反应完全一致,支持反应 adapted 手术策略。
要点
- CMR患者全部达MPR,PMD患者仅12.5%达MPR
- 索引淋巴结反应与全淋巴结床病理反应完全一致
- CMR后拒绝手术者随访无复发
核心结论
- [18F]FDG PET/CT代谢反应尤其是CMR与新辅助帕博利珠单抗后病理反应强相关。
- 索引淋巴结反应准确反映全淋巴结床反应,支持反应 adapted 手术策略。
研究设计与样本
- 回顾性分析 largely 前瞻性收集的数据,纳入两个荷兰黑色素瘤中心接受两周期新辅助帕博利珠单抗的可切除III期黑色素瘤患者。
- 治疗前后行[18F]FDG PET/CT,代谢反应按EORTC标准分类,病理反应按INMC标准评估。
主要发现
- 可评估PET/CT患者中CMR 12.5%、PMR 37.5%、SD 16.7%、PMD 33%。
- 总体59%达MPR;CMR者全部达MPR,PMR者64%达MPR,PMD者仅12.5%达MPR。
- 病理完全或近完全反应者均显示ΔTLG和ΔMTV下降。
- 所有可评估病例中索引淋巴结反应与全淋巴结床反应完全一致。
- 3例CMR后拒绝手术者随访期间无复发。
关键数值与推荐
- 代谢反应采用EORTC标准分类:CMR、PMR、SD、PMD。
- 病理反应采用INMC标准评估MPR。
- 可评估PET/CT患者中CMR 12.5%、PMR 37.5%、SD 16.7%、PMD 33%。
临床怎么用
- 可考虑用[18F]FDG PET/CT代谢反应尤其是CMR预测新辅助帕博利珠单抗后病理反应。
- 索引淋巴结反应可反映全淋巴结床反应,辅助反应 adapted 手术决策。
局限性
- 部分数据为前瞻性收集,非全部前瞻性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neoadjuvant immunotherapy is increasingly used in resectable stage III melanoma, with major pathological response (MPR) closely linked to improved outcomes. Predictive biomarkers are needed to identify responders and potentially allow surgical de-escalation. [¹⁸F]FDG-PET/CT is a non-invasive method to assess metabolic response, and the index lymph node (ILN) may reflect response of the entire nodal bain. METHODS: This retrospective analysis of largely prospectively collected data included patients with resectable stage III melanoma treated with two cycles of neoadjuvant pembrolizumab at two Dutch melanoma centres. [¹⁸F]FDG-PET/CT was performed before and after treatment, with metabolic response classified using EORTC criteria. Volumetric PET parameters, metabolic tumour volume (MTV) and total lesion glycolysis (TLG), were analysed retrospectively. Pathological response was assessed according to INMC criteria. In patients undergoing therapeutic lymph node dissection, ILN response was compared with the entire nodal basin. RESULTS: Forty-seven patients initiated neoadjuvant pembrolizumab, and 39 underwent surgery. Twenty-four patients had evaluable PET/CT scans: complete metabolic response (CMR) in 12.5%, partial metabolic response (PMR) in 37.5%, stable disease in 16.7%, and progressive metabolic disease (PMD) in 33%. Overall, 59% achieved MPR. All patients with CMR achieved MPR; 64% with PMR achieved MPR, compared with only 12.5% with PMD. All patients with pathological complete or near-complete response showed reductions in both ΔTLG and ΔMTV. ILN response was fully concordant with total nodal basin response in all evaluable cases. Three patients who declined surgery after CMR remained recurrence-free during follow-up. CONCLUSION: Metabolic response on [¹⁸F]FDG-PET/CT, particularly CMR, strongly correlates with pathological response after neoadjuvant pembrolizumab. ILN response accurately reflects total nodal basin response, supporting response-adapted surgical strategies.
引用
- Wilson MJ, Schurink AW, Schrage Y, et al. Predictive value of [18F]FDG PET/CT and index lymph node response following neoadjuvant pembrolizumab in resectable stage 3 melanoma: Real world data from the largest melanoma centres in the Netherlands. Eur J Cancer. 2026. PMID: 41895002. doi:10.1016/j.ejca.2026.116691
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。